drugset / Trial / NCT02370485

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

NCT02370485

Phase 1 Completed 23 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate how much of the LY2801653 drug is available in the body when given in 2 different formulations with and without a meal to healthy participants who are not able to have children. In addition, this study will measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study will last about 27 days. Screening is required within 28 days prior to the start of the study.

Timeline

Start
2015-02
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Merestinib Small molecule Oral

Indications

No indication recorded.